Health Care Reform and Business Development: 10 Reasons It Matters
The drama of the US health care reform debate is undeniable, but that doesn’t mean it’s easy to see how it will change the business of drug development. But it will, and we’ll give you 10 reasons why.
You may also be interested in...
Health Care Reform: For Biopharmas There Is Much To Like
The passage of health reform was a momentous juncture for the health care industry, but is also just the beginning of years of policy development that amend or define the crucial details of the 2010 proposals. Analysts are still tallying the reform bill's final cost to biopharma companies; even so, the industry stands to gain more it gives up with the landmark legislation's passing.
Building A Biopharma Product's Reimbursement Into Deals
The growing influence of payors means biopharma companies are grappling with how to incorporate the impact of reimbursement on a product’s market opportunity when structuring deals, executives said at the BIO-Windhover Pharmaceutical Strategic Outlook conference in New York City in February 2010.
Biopharma Trends: Nowhere To Go But Up
Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. VCs hunkered down as capital and exits remained scarce, and pharmaceutical acquirers remained cautious.Those deals that did get done were typically structured affairs or options-to-deal. In addition, health care reform added to the ongoing drama and uncertainty